10 WEEKS OF TIRZEPATIDE (MOUNJARO) ONLY $999! LOSE MORE WEIGHT WITH LESS SIDE EFFECTS!!

• Tirzepatide (Mounjaro) is a powerful new type 2 diabetes drug shown to be extremely effective for weight loss. It was recently approved for diabetes and is awaiting FDA approval for the primary treatment of obesity. It is a dual incretin agonist or a “twincreatin” that acts on TWO hunger hormone receptors: GIP and GLP-1. 

• In a press release from Eli Lilly in April of 2022, “GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids.” 

• Data from the first and largest of Lilly’s pivotal trials showed participants taking tirzepatide lost as much as 25 pounds on average over 40 weeks (with additional lifestyle modifications). Those who continued beyond 40 weeks, lost as much as 52 pounds! The average weight loss with tirzepatide is an astonishing 22.5%. 

• The manufacturer was offering a coupon that lowered the price to $25 per month for anyone who had a valid prescription. On 10/1/22, the coupon was changed and now requires a diagnosis of type 2 diabetes to be honored.

• We are able to offer a compounded version of tirzepatide that also contains added Vitamin b12. The side effects of tirzepatide are like GLP-1 medications and includes nausea and gastrointestinal disturbance. Most side effects are brief when the medication is started at the lowest dose and slowly increased over time. Like semaglutide, the medication is taken as a once-a-week nearly painless injection. 

• Tirzepatide targets areas of the brain that regulate appetite and satiety (sense of fullness after eating). It slows food digestion in the stomach, decreases appetite, diminishes food cravings, and increases feeling of fullness so you eat less and lose weight.

• Tirzepatide lowers blood pressure, improves blood sugars, improves insulin resistance, and reduces inflammation. It also lowers Hemoglobin A1C levels and enhance the function of β cells in the pancreas. 

• Treatment starts at a low dose and is increased slowly. This helps to improve tolerance and decrease side effects of the medication.

• Individual results vary and results are not guaranteed

Tirzepatide (Mounjaro) with its “twincreatin” action results in even greater weight loss and less side effects that semaglutide (Ozempic, Wegovy)